Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorHaukeland University Hospital
About this trial
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Eligibility criteria
Qualifiers
Included in OVERLORD-MS (NCT04578639)
Willing to attend laboratory for blood sample collection at scheduled time points
Disqualifiers
None
Trial design
Treatments tested in this trial
- Blood samples for PK
- Blood samples for PK
Treatment groups
No treatment groups listed
Sponsors and collaborators
Haukeland University Hospital
Lead sponsor
University of Bergen
Collaborator
Source ClinicalTrials.gov